Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2021

Open Access 01-12-2021 | Correction

Correction to: MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents

Authors: Arnold Bolomsky, Meike Vogler, Murat Cem Köse, Caroline A. Heckman, Grégory Ehx, Heinz Ludwig, Jo Caers

Published in: Journal of Hematology & Oncology | Issue 1/2021

Login to get access

Excerpt

The original article contains an incorrect affiliation for co-author, Meike Vogler. The correct affiliation can be viewed in this Correction article. …
Literature
1.
Metadata
Title
Correction to: MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
Authors
Arnold Bolomsky
Meike Vogler
Murat Cem Köse
Caroline A. Heckman
Grégory Ehx
Heinz Ludwig
Jo Caers
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2021
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-021-01043-z

Other articles of this Issue 1/2021

Journal of Hematology & Oncology 1/2021 Go to the issue

Review

Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target

Review

Combination strategies to maximize the benefits of cancer immunotherapy

Letter to the Editor

A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia

Letter to the Editor

Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohort

Correction

Correction to: Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells

Research

Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits